SPDR S&P Biotech ETF $XBI Stock Acquired by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC increased its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 20.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 180,000 shares of the exchange traded fund’s stock after purchasing an additional 30,000 shares during the quarter. SPDR S&P Biotech ETF accounts for 17.5% of Sivik Global Healthcare LLC’s portfolio, making the stock its largest position. Sivik Global Healthcare LLC owned 0.27% of SPDR S&P Biotech ETF worth $28,382,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. Vertrix Wealth Management LLC lifted its holdings in SPDR S&P Biotech ETF by 5.0% in the 3rd quarter. Vertrix Wealth Management LLC now owns 1,503 shares of the exchange traded fund’s stock worth $237,000 after buying an additional 71 shares in the last quarter. Compound Planning Inc. boosted its position in SPDR S&P Biotech ETF by 0.7% in the 1st quarter. Compound Planning Inc. now owns 10,889 shares of the exchange traded fund’s stock valued at $1,391,000 after buying an additional 75 shares during the last quarter. PeakShares LLC grew its stake in shares of SPDR S&P Biotech ETF by 5.2% during the first quarter. PeakShares LLC now owns 1,684 shares of the exchange traded fund’s stock valued at $215,000 after acquiring an additional 84 shares in the last quarter. Centaurus Financial Inc. grew its stake in shares of SPDR S&P Biotech ETF by 11.4% during the first quarter. Centaurus Financial Inc. now owns 1,254 shares of the exchange traded fund’s stock valued at $160,000 after acquiring an additional 128 shares in the last quarter. Finally, First Heartland Consultants Inc. grew its stake in shares of SPDR S&P Biotech ETF by 1.3% during the second quarter. First Heartland Consultants Inc. now owns 9,709 shares of the exchange traded fund’s stock valued at $1,536,000 after acquiring an additional 128 shares in the last quarter.

SPDR S&P Biotech ETF Stock Performance

Shares of NYSEARCA XBI traded down $3.93 during midday trading on Tuesday, reaching $147.47. 5,443,509 shares of the company’s stock were exchanged, compared to its average volume of 9,130,168. SPDR S&P Biotech ETF has a 52-week low of $103.43 and a 52-week high of $169.89. The stock has a market capitalization of $9.88 billion, a PE ratio of 11.47 and a beta of 0.83. The business’s fifty day moving average price is $158.67 and its two-hundred day moving average price is $146.36.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.